# US 2025/0145600 A1 · 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145600 A1
- Document ID: US20250145600A1
- Status: Published application
- Kind: A1
- Application number: 18/836,800
- Filed: 2023-02-10
- Published: 2025-05-08
- Earliest claimed: 2022-02-10
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Martin ALLAN; Matthew CARSON; Thomas CAYA; Tanzina FAZAL; Ming QIAN; Troy SMITH; Liansheng SU; Lihua YANG; Ping ZHANG
- Web page: https://patentgrep.com/patent/US20250145600A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 319/20: with substituents attached to the hetero ring
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds, as well as methods and uses of these compounds in the treatment of diseases.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
is a single or double bond;
is
wherein
indicates the point of attachment to the rest of the molecule;
W is O or CH2;
X is O or CH2;
R1 and R2 are each independently selected from H, C1-3-alkyl, halo and CN;
R3 is selected from H and C1-3-alkyl;
R4 and R5 are selected from:
(aa) R4 is selected from H, C1-6-alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, C3-6-cycloalkyl-C1-3-alkyl-, (4-10 membered heterocycloalkyl)-C1-3-alkyl-, phenyl-C1-3-alkyl-, halo, CN, NO2, OR4a, SR4a, C(O)R4b, C(O)NR4cR4d, C(O)NR4c(OR4a), C(O)NR4c(S(O)2R4b), C(O)NR4c(S(O)2NR4cR4d), NR4cOR4a, NR4cR4d, NR4c(C(O)R4b), NR4c(C(O)OR4a), N(OR4a)(C(O)R4b), NR4c(C(O)NR4cR4d), NR4c(C(O)NR4c(C(O)R4b)), NR4c(S(O)2R4), NR4c(S(O)2NR4cR4d), NR4c(C(O)NR4c(S(O)2R4b)), OC(O)R4b, OC(O)NR4cR4d, ONR4c(C(O)R4b), OS(O)2R4b, OP(O)(OR4e)(OR4f), S(O)OR4a, S(O)R4b, S(O)2R4b, S(O)2NR4cR4d, S(O)2OR4a, S(═NR4g)(O)R4b, S(═NR4g)(O)NR4cNR4d, P(O)(OR4e)(OR4f), and P(O)(OR4e)(R4f), wherein the C1-6-alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, C3-6-cycloalkyl-C1-3-alkyl-, (4-10 membered heterocycloalkyl)-C1-3-alkyl-, and phenyl-C1-3-alkyl- of R4 are each optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, OR4A, SR4A, C(O)R4B, C(O)NR4CR4D, C(O)NR4C(OR4A), C(O)NR4C(S(O)2R4B), C(O)NR4C(S(O)2NR4CR4D), NR4COR4A, NR4CR4D, NR4C(C(O)R4B), NR4C(C(O)OR4A), N(OR4A)(C(O)R4B), NR4C(C(O)NR4CR4D), NR4C(C(O)NR4C(C(O)R4B)), NR4C(S(O)2R4B), NR4C(S(O)2NR4CR4D), NR4C(C(O)NR4C(S(O)2R4B)), OC(O)R4B, OC(O)NR4CR4D, ONR4C(C(O)R4B), OS(O)2R4B, OP(O)(OR4E)(OR4F), S(O)OR4A, S(O)R4B, S(O)2R4B, S(O)2NR4CR4D, S(O)2OR4A, S(═NR4G)(O)R4B, S(═NR4G)(O)NR4CNR4D, P(O)(OR4E)(OR4F), and P(O)(OR4E)(R4F), and
R5 is 5-10 membered heteroaryl or (5-10 membered heteroaryl)-C1-3-alkyl-, wherein the 5-10 membered heteroaryl and (5-10 membered heteroaryl)-C1-3-alkyl- are each substituted with C(O)OR5A or with a carboxylic acid isostere, and optionally with 1, 2, or 3 groups independently selected from halo, CN, NO2, OR5A, SR5A, C1-3-alkyl, C1-3-alkyl substituted with 1, 2 or 3 halo, C(O)R5B, C(O)NR5CR5D, C(O)NR5C(OR5A), C(O)NR5C(S(O)2R5B), C(O)NR5C(S(O)2NR5CR5D), NR5COR5A, NR5CR5D, NR5C(C(O)R5B), NR5C(C(O)OR5A), N(OR5A)(C(O)R5B), NR5C(C(O)NR5CR5D), NR5C(C(O)NR5C(C(O)R5B)), NR5C(S(O)2R5B), NR5C(S(O)2NR5CR5D), NR5C(C(O)NR5C(S(O)2R5B)), OC(O)R5B, OC(O)NR5CR5D, ONR5C(C(O)R5B), OS(O)2R5B, OP(O)(OR5E)(OR5F), S(O)OR5A, S(O)R5B, S(O)2R5B, S(O)2NR5CR5D, S(O)2OR5A, S(═NR5G)(O)R5B, S(═NR5G)(O)NR5CNR5D, P(O)(OR5E)(OR5F), and P(O)(OR5E)(R5F); or
(bb) R4 is 5-10 membered heteroaryl or (5-10 membered heteroaryl)-C1-3-alkyl-, wherein the 5-10 membered heteroaryl and (5-10 membered heteroaryl)-C1-3-alkyl- are each substituted with C(O)OR4A or with a carboxylic acid isostere, and optionally with 1, 2, or 3 groups independently selected from halo, CN, NO2, OR4A, SR4A, C1-3-alkyl, C1-3-alkyl substituted with 1, 2 or 3 halo, C(O)R4B, C(O)NR4CR4D, C(O)NR4C(OR4A), C(O)NR4C(S(O)2R4B), C(O)NR4C(S(O)2NR4CR4D), NR4COR4A, NR4CR4D, NR4C(C(O)R4B), NR4C(C(O)OR4A), N(OR4A)(C(O)R4B), NR4C(C(O)NR4CR4D), NR4C(C(O)NR4C(C(O)R4B)), NR4C(S(O)2R4B), NR4C(S(O)2NR4CR4D), NR4C(C(O)NR4C(S(O)2R4B)), OC(O)R4B, OC(O)NR4CR4D, ONR4(C(O)R4B), OS(O)2R4B, OP(O)(OR4E)(OR4F), S(O)OR4A, S(O)R4B, S(O)2R4B, S(O)2NR4CR4D, S(O)2OR4A, S(═NR4G)(O)R4B, S(═NR4G)(O)NR4CNR4D, P(O)(OR4E)(OR4F), and P(O)(OR4E)(R4F), and
R5 is selected from H, C1-6-alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, C3-6-cycloalkyl-C1-3-alkyl, (4-10 membered heterocycloalkyl)-C1-3-alkyl-, phenyl-C1-3-alkyl-, halo, CN, NO2, OR5a, SR5a, C(O)R5b, C(O)NR5cR5d, C(O)NR5c(OR5a), C(O)NR5c(S(O)2R5b), C(O)NR5c(S(O)2NR5cR5d), NR5cOR5a, NR5cR5d, NR5c(C(O)R5b), NR5c(C(O)OR5a), N(OR5a)(C(O)R5b), NR5c(C(O)NR5cR5d), NR5c(C(O)NR5c(C(O)R5b)), NR5c(S(O)2R5b), NR5c(S(O)2NR5cR5d), NR5c(C(O)NR5c(S(O)2R5b)), OC(O)R5b, OC(O)NR5cR5d, ONR5c(C(O)R5b), OS(O)2R5b, OP(O)(OR5e)(OR5f), S(O)OR5a, S(O)R5b, S(O)2R5b, S(O)2NR5cR5d, S(O)2OR5a, S(═NR5g)(O)R5b, S(═NR5g)(O)NR5cNR5d, P(O)(OR5e)(OR5), and P(O)(OR5e)(R5), wherein the C1-6-alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, C3-6-cycloalkyl-C1-3-alkyl-, (4-10 membered heterocycloalkyl)-C1-3-alkyl-, and phenyl-C1-3-alkyl- of R5 are each optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, OR5A, SR5A, C(O)R5B, C(O)NR5CR5D, C(O)NR5C(OR5A), C(O)NR5C(S(O)2R5B), C(O)NR5C(S(O)2NR5CR5D), NR5COR5A, NR5CR5D, NR5C(C(O)R5B), NR5C(C(O)OR5A), N(OR5A)(C(O)R5B), NR5C(C(O)NR5CR5D), NR5C(C(O)NR5C(C(O)R5B)), NR5C(S(O)2R5B), NR5C(S(O)2NR5CR5D), NR5C(C(O)NR5C(S(O)2R5B)), OC(O)R5B, OC(O)NR5CR5D, ONR5C(C(O)R5B), OS(O)2R5B, OP(O)(OR5E)(OR5F), S(O)OR5A, S(O)R5B, S(O)2R5B, S(O)2NR5CR5D, S(O)2OR5A, S(═NR5G)(O)R5B, S(═NR5G)(O)NR5CNR5D, P(O)(OR5E)(OR5F), and P(O)(OR5E)(R5F); R6 is selected from (4-10 membered heterocycloalkyl)-C1-3-alkyl- and (5-10 membered heteroaryl)-C1-3-alkyl-, wherein the (4-10 membered heterocycloalkyl)-C1-3-alkyl- and (5-10 membered heteroaryl)-C1-3-alkyl- of R6 are each optionally substituted with 1, 2, or 3 groups independently selected from C1-6-alkyl, —OH, and halo;
R4a, R4b, R4c, and R4d are each independently selected from H, C1-6-alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C1-6-alkyl, C2-6 alkenyl, and C2-6 alkynyl of R4a, R4b, R4c, and R4d are each optionally substituted with 1, 2, or 3 groups independently selected from —OH and halo; and
the C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R4a, R4b, R4c, and R4d are each optionally substituted with 1, 2, or 3 groups independently selected from C1-6-alkyl, —OH, and halo;
R4c, R4f, and R4g are each independently selected from H and C1-6-alkyl;
R4A, R4B, R4C, and R4D are each optionally substituted with 1, 2, or 3 groups independently selected from —OH, halo and —OC(O)—C1-15-alkyl; and the C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkyl-C1-3-alkyl-, 5-10 membered heteroaryl, and phenyl of R4A, R4B, R4C, and R4D are each optionally substituted with 1, 2, or 3 groups independently selected from C1-6-alkyl, —OH, and halo;
R4E, R4F, and R4G are each independently selected from H and C1-6-alkyl;
R5a, R5b, R5c, and R5d are each independently selected from H, C1-6-alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C1-6-alkyl, C2-6 alkenyl, and C2-6 alkynyl of R5a, R5b, R5c, and R5d are each optionally substituted with 1, 2, or 3 groups independently selected from —OH and halo; and
the C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R5a, R5b, R5c, and R5d are each optionally substituted with 1, 2, or 3 groups independently selected from C1-6-alkyl, —OH, and halo;
R5c, R5f, and R5g are each independently selected from H and C1-6-alkyl;
R5A, R5B, R5C, and R5D are each optionally substituted with 1, 2, or 3 groups independently selected from —OH, halo and —OC(O)—C1-15-alkyl; and the C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkyl-C1-3-alkyl-, 5-10 membered heteroaryl, and phenyl of R5A, R5B, R5C, and R5D are each optionally substituted with 1, 2, or 3 groups independently selected from C1-6-alkyl, —OH, and halo; and
R5E, R5F, and R5G are each independently selected from H and C1-6-alkyl.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is chloro, fluoro or CN, R2 is chloro or fluoro, and R3 is —CH3.

### Claim 3 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from C1-3-alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and halo, wherein the C1-3-alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, and phenyl of R4 are each optionally substituted with 1, 2, or 3 groups independently selected from halo and C1-3-alkyl, and R5 is 5-10 membered heteroaryl or (5-10 membered heteroaryl)-C1-3-alkyl-, wherein the 5-10 membered heteroaryl and (5-10 membered heteroaryl)-C1-3-alkyl- are each substituted with C(O)OR5A or with a carboxylic acid isostere, and optionally with 1, 2, or 3 groups independently selected from halo, C1-3-alkyl and C1-3-alkyl substituted with 1, 2 or 3 halo; wherein R5A is selected from H and C1-3-alkyl.

### Claim 4 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is C1-3-alkyl or C1-3-alkyl substituted with 1, 2 or 3 halo.

### Claim 5 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is 5-10 membered heteroaryl or (5-10 membered heteroaryl)-C1-3-alkyl-, wherein the 5-10 membered heteroaryl and (5-10 membered heteroaryl)-C1-3-alkyl- are each substituted with C(O)OR4A or with a carboxylic acid isostere, and optionally with 1, 2, or 3 groups independently selected from halo, C1-3-alkyl and C1-3-alkyl substituted with 1, 2 or 3 halo; wherein R4A is selected from H and C1-3-alkyl, and R5 is selected from C1-3-alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, and halo, wherein the C1-3-alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6-cycloalkyl, 4-10 membered heterocycloalkyl, and phenyl are each optionally substituted with 1, 2, or 3 groups independently selected from halo and C1-3-alkyl.

### Claim 6 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R5 is C1-3-alkyl or C1-3-alkyl substituted with 1, 2 or 3 halo.

### Claim 7 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R4 is 5-10 membered heteroaryl substituted with C(O)OR4A, and optionally with 1, 2, or 3 groups independently selected from halo, C1-3-alkyl and C1-3-alkyl substituted with 1, 2 or 3 halo; wherein R4A is selected from H and C1-3-alkyl.

### Claim 8 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R4 has the structure of Formula H1a or H2a:
wherein the ring is aromatic; wherein
X1 is C, and each of X2, X3, X4, X5, and X6 is independently C═O, CR4h, NR4i, O, or S, wherein at least one of X2-X6 is N, O, or S;
R4A is selected from H and C1-3-alkyl; and
if present, R4h is halo, C1-3-alkyl or C1-3-alkyl substituted with 1, 2 or 3 halo, and R4i is C1-3-alkyl.

### Claim 9 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from the group consisting of:
wherein Ra, Rb and Rc are independently selected from H, C1-3-alkyl and C1-3-alkyl substituted with 1, 2 or 3 halo, and R4A is selected from H and C1-3-alkyl.

### Claim 10 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R5 is 5-10 membered heteroaryl substituted with C(O)OR5A, and optionally with 1, 2, or 3 groups independently selected from halo, C1-3-alkyl and C1-3-alkyl substituted with 1, 2 or 3 halo; wherein R5A is selected from H and C1-3-alkyl.

### Claim 11 (depends on 10)

The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R5 has the structure of Formula H11a or H12a:
wherein the ring is aromatic; wherein
X1 is C, and each of X2, X3, X4, X5, and X6 is independently C═O, CR5h, NR5i, O, or S, wherein at least one of X2-X6 is N, O, or S;
R5A is selected from H and C1-3-alkyl; and
if present, R5h is halo, C1-3-alkyl or C1-3-alkyl substituted with 1, 2 or 3 halo, and R5i is C1-3-alkyl.

### Claim 12 (depends on 10)

The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R5 is selected from the group consisting of
wherein Ra, Rb and Rc are independently selected from H, C1-3-alkyl and C1-3-alkyl substituted with 1, 2 or 3 halo, and R5A is selected from H and C1-3-alkyl.

### Claim 13 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is selected from (4-6 membered heterocycloalkyl)-CH2— and (5-6 membered heteroaryl)-CH2—, wherein the (4-6 membered heterocycloalkyl)-CH2— and (5-6 membered heteroaryl)-CH2— of R6 are each optionally substituted with 1, 2, or 3 groups independently selected from C1-6-alkyl, —OH, and halo.

### Claim 14 (depends on 13)

The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein R6 is of formula:
wherein indicates the point of attachment to the rest of the molecule.

### Claim 15 (depends on 1)

The compound according to claim 1, which is a compound of formula (IIa):
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound according to claim 1, which is a compound of formula (IIIa):
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The compound according to claim 1, which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-5-methyloxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((R)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-5-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((R)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-4-(trifluoromethyl)-1H-imidazol-5-yl)oxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-ethyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-ethyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-5-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-ethyl-1-(((R)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-ethyl-1-(((R)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-5-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-5-ethyloxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-5-methyloxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-5-methyloxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-4-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-4-(trifluoromethyl)oxazole-5-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-4-methyloxazole-5-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-2-carboxylic acid,
3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1-methyl-1H-pyrazole-5-carboxylic acid,
4-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-2-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-3-methylfuran-2-carboxylic acid,
4-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-2-carboxylic acid,
3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-1-methyl-1H-pyrazole-5-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)furan-2-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)nicotinic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)furan-2-carboxylic acid,
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-5-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1,3,4-oxadiazole-2-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)isoxazole-3-carboxylic acid,
3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)isoxazole-5-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid,
5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)nicotinic acid,
4-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)thiazole-2-carboxylic acid, and
2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-5-carboxylic acid, and
ethyl 2-(2-((4-((S)-2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-5-methyloxazole-4-carboxylate,
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

### Claim 20 (depends on 1)

A combination comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents.

### Claim at position 21

21-23. (canceled)

### Claim 24 (depends on 1)

A method of agonizing GLP1R activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

A method of treating a disorder or disease selected from obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease, and neuropathy in a subject, comprising administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.
